Hepatitis C Genotype 1 (GT 1) Patients in the United States (US)
|
|
- Peter Morton
- 5 years ago
- Views:
Transcription
1 Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) INDICATION is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection. 1
2 RECOMMENDED TREATMENT DURATION FOR HCV GT 1, 4, 5, OR 6 PATIENTS, INCLUDING THOSE WITH HCV/HIV-1 CO-INFECTION Please refer to the Drug Interactions section of the full Prescribing Information for dosage recommendations for concomitant HIV-1 antiviral drugs. 1 TABLET DAILY NO FOOD REQUIREMENT 8 + RBV Can be considered in treatment-naïve (TN) GT 1 patients without cirrhosis and with pre-treatment HCV RNA <6 million IU/mL TN GT 1 patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) Treatment-experienced (TE) a GT 1 patients without cirrhosis TN or TE a GT 4, GT 5 or GT 6 patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) TN and TE a GT 1 patients with decompensated cirrhosis (Child-Pugh B or C) b TN and TE a GT 1 or GT 4 liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh A) c 24 TE a GT 1 patients with compensated cirrhosis (Child- Pugh A) d a TE patients include those who have failed a peginterferon alfa + ribavirin (RBV)-based regimen with or without an HCV protease inhibitor. b In patients with decompensated cirrhosis (Child-Pugh B or C), the starting dosage of RBV is 600 mg and can be titrated up to 1000 mg for patients <75 kg and 1200 mg for those 75 kg in two divided doses with food. If the starting dosage of RBV is not well tolerated, the dosage should be reduced as clinically indicated based on hemoglobin levels. c The daily dosage of RBV is weight-based (1000 mg for patients <75 kg and 1200 mg for those 75 kg) administered orally in two divided doses with food. Refer to the RBV prescribing information. d + RBV for 12 weeks can be considered in TE GT 1 patients with compensated cirrhosis who are eligible for RBV. See footnote c for RBV dosage recommendations. ESTIMATED DISPOSITION OF CHRONIC HCV GT 1 PATIENTS IN THE US An estimated 3.5 million people in the US have chronic HCV. 2 Insight into the disposition of the HCV population receiving medical care in the US may help payers predict the size and scope of HCV management among their members. Contraindications If is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information. Warnings and Precautions Risk of Serious Symptomatic Bradycardia When Coadministered with Amiodarone: Amiodarone is not recommended for use with due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
3 The Ipsos Therapy Monitor study 3 is a standardized chart audit that records how physicians are managing their patients who have chronic HCV. These data provide a snapshot of the estimated percentages of GT 1, GT 4, GT 5, and GT 6 patients in the US who are receiving medical care 3 Overall, the genotype distribution in this study is consistent with the Centers for Disease Control and Prevention (CDC) estimates within the US population. 3,4 Among chronic HCV patients in this survey, approximately three-quarters were TN and less than one-quarter were TE (this may include experience with prior HCV protease inhibitors) 3 Ipsos Chart Audit January - December 2015 (N = 4910): estimated treatment experience distribution among HCV patients 3,a 3% 12% 19% 66% GT 1, TN GT 1, TE GT 4, 5, 6 a N = 4910 chronic HCV patients in the US (includes all patients with known genotype excluding those with sustained virologic response [SVR] or awaiting SVR results [weighted]). Other genotypes Ipsos Chart Audit January - December 2015 (N = 3021): estimated disposition by treatment experience and cirrhosis status among GT 1 patients 3,a a N = 3021 GT 1 chronic HCV patients in the US (includes all GT 1 patients with known fibrosis score [weighted]). Presence of cirrhosis was defined by a METAVIR fibrosis score of F4. 11% 17% 7% 65% GT 1, TN, noncirrhotic GT 1, TN, cirrhotic GT 1, TE, noncirrhotic GT 1, TE, cirrhotic 9% Ipsos Chart Audit January - December 2015 (N = 3021): disposition by METAVIR fibrosis score among GT 1 patients 3 24% 19% 28% 20% F0 (no liver damage) F1 (minimal liver damage) F2 (moderate liver damage) F3 (advanced liver damage) F4 (cirrhotic) Warnings and Precautions (continued) Risk of Reduced Therapeutic Effect of Due to P-gp Inducers: Rifampin and St. John s wort are not recommended for use with as they may significantly decrease ledipasvir and sofosbuvir plasma concentrations.
4 A patient chart review based on online/mobile surveys with HCV-treating physicians tracked the intended duration of therapy for prescriptions within the US over time. This information can help provide a context for payers to estimate the number of patients that physicians may consider eligible for 8 weeks of therapy. Based on the most recent data available from 196 physicians representing 5368 patient charts, was initiated in 2063 TN, noncirrhotic (NC), GT 1 patients. Of those patients, 81% had a baseline viral load of <6 million (M) IU/mL. The following two figures show the intended lengths of therapy with for TN, NC, GT 1 patients with a viral load of <6M IU/mL first by average and then over time. 5 HCV Patient Initiation Tracker January 5, January 3, 2016 (n = 1677): intended length of therapy (LOT) among TN, NC GT 1 patients with baseline viral load <6M IU/mL average 5 Initiations LOT (average) TN, NC GT 1 Patients with Baseline Viral Load <6M IU/mL (n = 1677) 8 weeks 68% 12 weeks 31% Other 1% Many TN, NC GT 1 patients with a viral load <6M IU/mL may be considered for an 8 week regimen. 1,3,5 HCV Patient Initiation Tracker January 5, January 3, 2016 (n = 1677): LOT among TN, NC GT 1 patients with baseline viral load <6M IU/mL over time 5 3% 1% 1% 33% 34% 27% 31% % of Patient Charts 64% 66% 72% 68% 8 weeks 12 weeks Other Q /05/15 to 03/29/15 (n = 357) Q /30/15 to 06/21/15 (n = 405) Q /22/15 to 09/27/15 (n = 440) Q /28/15 to 01/03/16 (n = 475) Physicians were asked: What is the intended total length of therapy for the patient on? Warnings and Precautions (continued) Related Products Not Recommended: is not recommended for use with other products containing sofosbuvir. Adverse Reactions Most common ( 10%, all grades) adverse reactions were fatigue, headache and asthenia.
5 The fibrosis score distribution of GT 1 patients who could be considered to receive 8 weeks of (TN, NC with a baseline viral load <6M IU/mL) and received an intended 8 week LOT are shown in the chart below. HCV Patient Initiation Tracker January 5, January 3, 2016 (n = 1130): intended LOT and fibrosis distribution among GT 1 patients who could be considered for an 8 week LOT (TN, NC with a baseline viral load <6M IU/mL) 5 % of Patient Charts 35% 35% 22% 8% F3 (advanced liver damage) F2 (moderate liver damage) F1 (minimal liver damage) F0 (no liver damage) 8 Week (n = 1130) AASLD/IDSA recommends early treatment for chronic HCV 6 [Clinicians] should treat HCV-infected patients with antiviral therapy with the goal of achieving an SVR, preferably early in the course of their chronic HCV infection before the development of severe liver disease and other complications. AASLD/IDSA Guidance 6 AASLD = American Association for the Study of Liver Diseases; IDSA = Infectious Diseases Society of America; SVR = sustained virologic response. Drug Interactions In addition to rifampin and St. John s wort, coadministration of is also not recommended with carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifapentine, and tipranavir/ritonavir. Such coadministration is expected to decrease the concentration of ledipasvir and sofosbuvir, reducing the therapeutic effect of. Coadministration of is not recommended with simeprevir due to increased concentrations of ledipasvir and simeprevir. Coadministration is also not recommended with rosuvastatin or co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate due to increased concentrations of rosuvastatin and tenofovir, respectively. Consult the full Prescribing Information for for more information on potentially significant drug interactions, including clinical comments.
6 References: 1. full Prescribing Information, Foster City, CA: Gilead Sciences, Inc; February Yehia BR, Schranz AJ, Umscheid CA, et al. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLos ONE (7):e Ipsos HCV USA. Therapy Monitor. Q Q National Institutes of Health Consensus Development Conference statement: management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology. 2002; 123: ZoomRx. HCV Initiation Chart Audit. HCV Initiation Tracker. January 5, 2015 to January 3, AASLD/IDSA/IAS USA. When and in whom to initiate HCV therapy. Summary of recommendations for when and in whom to initiate HCV therapy. Recommendations for testing, managing, and treating hepatitis C. Updated February 24, Accessed February 26, 2016., the logo, GILEAD, and the GILEAD logo are trademarks of Gilead Sciences, Inc. or its related companies Gilead Sciences, Inc. All rights reserved. HVNP /16
Update on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationPatient Discussion Guide
Patient Discussion Guide INFORMATION AND ANSWERS TO AID YOUR COUNSELING OF PATIENTS Please click to see full Prescribing Information for HARVONI, including BOXED WARNING. CHRONIC HEPATITIS C (HEP C) GENOTYPE
More informationSOFOSBUVIR/VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR
Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR EPCLUSA 43561 GUIDELINES FOR USE 1. Is the patient at least 18 years old? If yes, continue to #2. 2. Does the patient have a diagnosis of
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationGilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting 2018
Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting 2018 October 11, 2018 3:24 PM ET -- More Than 50 Abstracts Across NASH, PSC, HBV and HCV Reflect
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationHighlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting
December 16 Volume 12, Issue 12, Supplement 6 A SPECIAL MEETING REVIEW EDITION Highlights in the Treatment of Hepatitis C Virus From the 16 AASLD Liver Meeting A Review of Selected Presentations From the
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationINFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL
Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationAdvances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting
June 2016 Volume 12, Issue 6, Supplement 2 A SPECIAL MEETING REVIEW EDITION Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting The Annual Meeting of the European Association
More informationHepatits C Criteria Direct Acting Antiviral Medications
Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis
More informationDescription of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases
Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other SOFOSBUVIR/VELPATASVIR EPCLUSA TBD CUSTOMER SERVICE REPRESENTATIVE (CSR) If the member lives in Rhode Island or if the prescribing physician
More informationEpclusa (Sofosbuvir/Velpatasvir) for HIV/HCV
Mountain West AIDS Education and Training Center Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV John Scott, MD, MSc Associate Professor University of Washington Jul 28, 2016 This presentation is intended
More informationZepatier. (elbasvir, grazoprevir) New Product Slideshow
Zepatier (elbasvir, grazoprevir) New Product Slideshow Introduction Brand name: Zepatier Generic name: Elbasvir, grazoprevir Pharmacological class: HCV NS5A inhibitor + HCV NS3/4A protease inhibitor Strength
More informationHarvoni: solution to HCV
Harvoni: solution to HCV PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP Hepatitis C (HCV) Inflammation of the liver,
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationOutpatient Pharmacy Effective Date: August 15, 2014
Therapeutic Class Code: W5Y, W5V, W0B, W0D, W0A, W0E Therapeutic Class Description: Hepatitis C Virus nucleotide analog NS5B RNA Dependent Polymerase Inhibitor, Hepatitis C Virus NS3/4A Serine Protease
More informationONE REGIMEN, ALL GENOTYPES, 8 WEEKS
For UK healthcare professionals only INTRODUCING MAVIRET ONE REGIMEN, ALL GENOTYPES, 8 WEEKS FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS 1 Maviret is indicated for the treatment of chronic hepatitis C
More informationGenotype 4, 5, or 6. Genotype. Genotype 4, 5, or 6
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LEDIPASVIR and SOFOSBUVIR TABLETS safely and effectively. See full prescribing information for LEDIPASVIR
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2052-10 Program Prior Authorization/Medical Necessity Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 4/2015, 8/2015,
More informationJOHNS HOPKINS HEALTHCARE
JOHNS HOPKINS HEALTHCARE Subject: Clinical Criteria for Hepatitis C (HCV) Therapy Department: Pharmacy Lines of Business: PPMCO Policy Number: MEDS92 Effective Date: 04/15/2015 Revision Date: 08/15/2015
More informationand Duration HARVONI 12 weeks HARVONI 12 weeks HARVONI 24 weeks 12 weeks
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (ledipasvir and sofosbuvir) tablets,
More informationREQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments
Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Harvoni) Reference Number: CP.CPA.175 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 32 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationPegylated Interferon Agents for Hepatitis C
Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection
More informationSubject: Hepatitis C Drug Therapy
09-J0000-53 Original Effective Date: 01/01/06 Reviewed: 07/11/18 Revised: 11/15/18 Subject: Hepatitis C Drug Therapy THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationGeneral Statement for Drugs for the Treatment of Hepatitis C
General Statement for Drugs for the Treatment of Hepatitis C Use the following criteria to determine patient eligibility for subsidisation under the PBS for hepatitis C treating agents. By writing a PBS
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationGenotype 2. Genotype 3
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SOVALDI safely and effectively. See full prescribing information for SOVALDI. SOVALDI (sofosbuvir)
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationHarvoni (Ledipasvir/Sofosbuvir) Information Packet
Harvoni (Ledipasvir/Sofosbuvir) Information Packet Family Medicine Provider: If you are considering hepatitis C treatment, please read this treatment agreement carefully and be sure to ask any questions
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationHepatitis C Virus Management
Hepatitis C Virus Management FDA-Approved Medications Hepatitis C is caused by a virus and results in liver inflammation, which can lead to advanced liver disease and/or liver cancer. An estimated 3 to
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Harvoni Page: 1 of 7 Last Review Date: June 19, 2015 Harvoni Description Harvoni (ledipasvir &
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.32 Subject: Harvoni Page: 1 of 7 Last Review Date: December 3, 2015 Harvoni Description Harvoni (ledipasvir
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: Last Review Date: 06.18
Clinical Policy: (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: 01.01.17 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
AUSTRALIAN PI EPCLUSA (sofosbuvir/velpatasvir) 1 ME OF THE MEDICINE EPCLUSA (sofosbuvir/velpatasvir 400 mg/100 mg) tablets. The active substances in EPCLUSA tablets are sofosbuvir and velpatasvir. 2 QUALITATIVE
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: CP.CPA.283 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Daklinza) Reference Number: CP.CPA.283 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationSofosbuvir (Sovaldi) Drug Summary. Class and Mechanism. Table of Contents
Hepatitis C Online PDF created July 12, 2018, 1:44 pm Sofosbuvir (Sovaldi) Table of Contents Sofosbuvir Sovaldi Editor's Summary Drug Summary Class and Mechanism Manufacturer for United States Cost and
More informationClinical guidelines for the treatment of hepatitis C in Iceland
F the Treatment as Prevention f Hepatitis C in Iceland (TraP Hep C) A nationwide campaign f reducing disease burden using combination antiviral treatment Whom to treat All patients infected with the hepatitis
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
April 1, 2017 Bulletin #165 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Related Information for Prescribers: Only prescribers who have completed
More informationAmeriHealth Caritas Iowa Request for Prior Authorization Hepatitis C Treatments
Form applies to IA Health Link and hawk-i plans. Please print accuracy is important. Fax completed form to 1-855-825-2714. Provider Help Desk: 1-855-328-1612. AmeriHealth Caritas Iowa member ID #: Patient
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August
BRAND NAME Technivie GENERIC NAME Ombitasvir/paritaprevir/ritonavir MANUFACTURER AbbVie, Inc. DATE OF APPROVAL February 27, 2017 PRODUCT LAUNCH DATE Already available on the market REVIEW TYPE Review type
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: Last Review Date: 06.18
Clinical Policy: (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: 08.01.17 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationCalifornia Department of Health Care Services Utilization and Treatment Policy for Simeprevir and Sofosbuvir in the Management of Hepatitis C
Introduction California Department of Health Care Services Utilization and Treatment Policy for Simeprevir and Sofosbuvir in the Management of Hepatitis C This policy was developed by the California Department
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: March 18, 2016 Harvoni Description Harvoni (ledipasvir
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: December 2, 2016 Harvoni Description Harvoni (ledipasvir
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis B / Hepatitis C Peg-interferon Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis B / Hepatitis C Peg-interferon Hepatitis
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Epclusa) Reference Number: CP.CPA.286 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1 SOVALDI (SOFOSBUVIR 400 MG) TABLETS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sofosbuvir 400 mg. For full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)
More informationHepatitis C Virus Clinical Criteria Update September 18, For: New York State Medicaid
Hepatitis C Virus Clinical Criteria Update September 18, 2014 For: New York State Medicaid 1 Purpose Characterize the place in therapy for the agents utilized for management of chronic hepatitis C (CHC)
More informationHCT Pharmaceutical Policy
HCT Pharmaceutical Policy Treatment of Chronic Hepatitis C Policy # HCT118 Current Effective Date: 10/6/2015 Pharmaceutical Policies are developed by HealthyCT to assist in administering plan benefits
More informationTreatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationClinical Policy: Ledipasvir/Sofosbuvir (Harvoni) Reference Number: HIM.PA.SP3 Effective Date: Last Review Date: Line of Business: HIM
Clinical Policy: (Harvoni) Reference Number: HIM.PA.SP3 Effective Date: 08.01.16 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationPharmacy Medical Necessity Guidelines: Hepatitis C Virus
Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX)
More informationHEPCVEL Tablets (Sofosbuvir 400 mg + Velpatasvir 100 mg)
Published on: 3 Jul 2017 HEPCVEL Tablets (Sofosbuvir 400 mg + Velpatasvir 100 mg) Black Box Warning Risk of Hepatitis B Virus Reactivation in Patients Co-Infected with HCV And HBV Test all patients for
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationClinical Policy: Simeprevir (Olysio) Reference Number: CP.CPA.289 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Olysio) Reference Number: CP.CPA.289 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationCost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection
Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection The NCPE has issued a recommendation regarding the cost
More informationVemlidy. (tenofovir alafenamide) New Product Slideshow
Vemlidy (tenofovir alafenamide) New Product Slideshow Introduction Brand name: Vemlidy Generic name: Tenofovir alafenamide Pharmacological class: Nucleoside analogue (reverse transcriptase inhibitor) Strength
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationSovaldi (sofosbuvir) GA Medicaid
Sovaldi (sofosbuvir) GA Medicaid Override(s) Prior Authorization Quantity Limit Medication Sovaldi (sofosbuvir) Approval Duration Based on Genotype, Treatment status, Cirrhosis status, Hepatocellular Carcinoma
More informationProtocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018)
PREFERRED AGENTS: (See drug specific NOTES for exceptions.) Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018) https://providers.amerigroup.com For genotype 1, Mavyret and
More informationOmbitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak) Prepared by: Sophie Woolston, MD and David H. Spach, MD Last Updated: December 29, 2014 OMBITASVIR-PARITAPREVIR-RITONAVIR
More informationOn Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018
On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018 Trana Hussaini, PharmD Pharmacotherapy Specialist in Liver Transplantation, VGH Clinical Assistant Professor, Faculty of Pharmaceutical
More informationHepatitis B virus (HBV) reactivation has been reported, in some cases resulting in fulminant hepatitis, hepatic failure, and death. (5.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OLYSIO safely and effectively. See full prescribing information for OLYSIO. OLYSIO (simeprevir) capsules,
More information/ / Please provide contact information and indicate ONE method of preferred contact for notification of the results: me at:
Please note that the patient AND physician must complete this form. All fields are mandatory and must be completed. Incomplete forms may result in your application being declined. Please retain a copy
More informationProfessor Mark Nelson. Chelsea and Westminster Hospital, London, UK
Professor Mark Nelson Chelsea and Westminster Hospital, London, UK Treatment should be prioritized Treatment Indicated All naive and experienced pts with liver disease Prioritized Pts with fibrosis (F3)
More informationGenotype 1 or weeks. Genotype 2 SOVALDI + ribavirin 12 weeks. Genotype 3 SOVALDI + ribavirin 24 weeks
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SOVALDI safely and effectively. See full prescribing information for SOVALDI. SOVALDI TM (sofosbuvir)
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: () Reference Number: CP.HNMC.178 Effective Date: 11.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Sofosbuvir (Sovaldi) Reference Number: OH.PHAR.PPA.12 Effective Date: Last Review Date: 12.18
Clinical Policy: (Sovaldi) Reference Number: OH.PHAR.PPA.12 Effective Date: 01.19 Last Review Date: 12.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSOLAR-1 (Cohorts A and B)
Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; 149:649-59. Ledipasvir-Sofosbuvir
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPA.131 Effective Date:
Clinical Policy: (Daklinza) Reference Number: ERX.SPA.131 Effective Date: 10.01.16 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationHepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) QUEST Integration Formulary
Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) QUEST Integration Formulary Policy Number: Original Effective Date: MM.04.036 06/01/2015 Lines of Business: Current Effective
More informationMAVYRET (glecaprevir, pibrentasvir ) NEW PRODUCT SLIDESHOW
MAVYRET (glecaprevir, pibrentasvir ) NEW PRODUCT SLIDESHOW Introduction Brand name: Mavyret Generic name: Glecaprevir, pibrentasvir Pharmacological class: HCV NS3/4A protease inhibitor + HCV NS5A inhibitor
More informationNew Exception Status Benefits
MARCH 2015 Nova Scotia Formulary Updates New xception Status Benefits Harvoni (ledipasvir/sofosbuvir) Sovaldi (sofosbuvir) BRO LLIPTA (fluticasone furoate/vilanterol (as trifenatate)) Onglyza (saxagliptin)
More informationNew Exception Status Benefits
APRIL 2018 Nova Scotia Formulary Updates New Exception Status Benefits Lenvima Updates for Hepatitis C Medications Daklinza Epclusa Harvoni Sovaldi Zepatier New Diabetic Product New Ostomy Products Nova
More information